LATUDA® (lurasidone) for the treatment of schizophrenia
Sunovion currently markets the antipsychotic lurasidone in the UK and selected countries in Europe for the treatment of schizophrenia in adults.
Adverse reactions should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard
Adverse reactions should also be reported to Sunovion Pharmaceuticals Europe Ltd. on +44 20 7821 2899.
For more information about lurasidone visit:
Sunovion Pharmaceuticals Europe Ltd is sponsoring a non-interventional, observational study. Details can be found at http://www.encepp.eu/encepp/viewResource.htm?id=28736
Sunovion by the numbers
- Top 20 One of the fastest-growing among top U.S. pharmaceutical companies*
- 1,620 employees worldwide
- 30K employee volunteer hours in 8 years